All of Us Pennsylvania Research Program
You may be able to change the future of medicine. The All of Us PA Research Program is enrolling adults 18 years of age or older. This may be your chance to improve how your children and your children’s children receive medical care.
Experiences of Men with Cancer - Questionnaire
Are you an adult male with a past or current cancer diagnosis? If so, you may be able to participate in a research study to help better understand how men with cancer stand up for themselves (called “self-advocacy”). Involves completing questionnaires (paper or online) that will take about 30-45 minutes. Compensation provided.
Experiences of Return-to-Work in Registered Nurses with Cancer
Are you a nurse who has been treated for cancer? You may be able to participate in a study about your return-to-work experiences. Participation involves completing a 10-15 minute questionnaire and a 90-120 minute focus group interview. Compensation is provided.
DESTINY-Breast05 Research Study
Have you been diagnosed with HER-2 positive breast cancer? Did you complete your chemotherapy treatment and undergo surgery for your cancer within the past 12 weeks? You may be able to participate in a study to see if a drug called T-DXd is effective in treating people with HER2-positive early breast cancer. This study involves multiple visits, including follow-up visits for up to 10 years.
Prescription Opioid and Chronic Pain Stigma in Cancer Survivors Study
Did you complete treatment for cancer at least 6 months ago and are still experiencing pain? You may be able to participate in a study to better understand chronic pain and opioid stigma in cancer survivors. Participation consists of one interview that takes between 30 and 45 minutes to complete, followed by a brief demographic questionnaire. Compensation is provided.
Are you currently receiving chemo for cancer at UPMC? Do you have a smartphone? You may be able to participate in a study to monitor symptoms during chemotherapy using smartphones and Fitbits. Participation involves installing study apps on your smartphone and completing daily questionnaires for 90 days. Compensation is provided.
MyPaTH Story Booth 2.0
Interested in sharing your story about health, illness, or research? Patients and caregivers are needed to participate in a research study to help learn more about topics that are important to you and that may improve health and health care. Participation involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
MyPaTH Story Booth – COVID-19 Stories
Participants are invited to share how they are maintaining their health during the coronavirus pandemic, or to share what it is like being ill with COVID-19 and/or caring for a loved one who is ill with COVID-19. Participation in this research study involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
Writing Interventions for Aromatase Inhibitor Medication Adherence Study
Were you prescribed an aromatase inhibitor (AI) in the past 4 weeks, or will you be prescribed an AI in the future? You may be eligible for a remote research study to test whether a writing intervention improves medication adherence and reduces physical symptoms and stress. This study involves questionnaires, writing activities, and the use of an electronic pill bottle. Compensation is provided.
HCC 17-142: MORPHEUS-HR+ Breast Cancer Study
Have you been diagnosed with hormone receptor-positive, HER-2 negative breast cancer that has spread to other parts of your body? Has your disease worsened during or after treatment with a CDK4/6 inhibitor? If so, you may be able to participate in a research study to compare the effects of experimental drug treatment versus standard treatment on you and your breast cancer.
Telehealth and Memory Study
Are you a breast cancer survivor who completed chemotherapy one to five years ago? Do you have problems with your memory, concentration, and/or attention? You may be able to participate in a research study to test two treatments that may help breast cancer survivors improve cognitive function. This study involves 8 weeks of therapy completed online or by mobile phone, and optional MRI scanning.
HCC 20-195: HER2+ Breast Cancer Study
Do you have HER2-positive breast cancer that may have spread to other parts of your body? You may be able to participate in a research study to find out if the combination of two anti-cancer study drugs is a safe and effective treatment for adults with advanced HER2-positive breast cancer. Reimbursement for study visits is provided.
HER2-Positive Breast Cancer with Brain Metastases: HCC 19-005 (TBCRC 022)
Do you have HER2-positive breast cancer that has spread to the brain? If so, you may be eligible to participate in a research study to help find out if an investigational combination of drugs called ado-trastuzumab emtansine (also known as T-DM1 or Kadcyla®) and neratinib (also known as Nerlynx®) is safe and effective for people with HER2-positive breast cancer that has spread to the brain.
Have you been diagnosed with hormone receptor positive or triple negative breast cancer that is growing on your chest wall (chest wall disease)? If so, you may be eligible to participate in a study to help researchers see what effects, good or bad, the combination of pembrolizumab (KEYTRUDA) and carboplatin (chemotherapy) have on your cancer compared to carboplatin alone.
Are you a woman age 40 or up who has been newly diagnosed (past 3 months) with non-invasive ductal carcinoma in situ (DCIS)? If so, you may be eligible for a study to help researchers evaluate the risks and benefits of usual treatment approach for DCIS vs. close monitoring approach. Study participation will last at least 5 years.
Endocrine Response in Women with Invasive Lobular Breast Cancer (ILC) (TBCRC 037)
Are you a postmenopausal woman with newly diagnosed invasive lobular breast cancer (ILC)? If so, you may be able to participate in a research study to learn more about how tumors respond to hormonal therapy in this population.